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background:  The relationship between LDL-C measured at the time of an ACS event and subsequent treatment benefit from LDL-C 
lowering is poorly understood.
methods:  The IMPROVE IT trial randomized 18,144 patients post-ACS to either ezetimibe or placebo, on a background of simvastatin 
40-80 mg. We compared clinical outcomes in all subjects (and also in the 11,504 patients naive to lipid therapy at baseline), stratified by 
quartiles of baseline LDL-C. Follow-up was for a median of ~6 years. Multivariable models assessed whether the treatment benefit was 
dependent on baseline LDL-C. The primary endpoint was a composite of CV death, major coronary events, or non-fatal stroke. 
Results:  Results of the main IMPROVE-IT trial will be available in November 2014. We plan to present the adjusted HR of the primary 
endpoint, stratified by LDL-C quartile (<65, 65-80, 80-96, >96 mg/dL). Adjusted interaction tests between treatment and highest versus 
lowest baseline LDL-C quartile will be presented as well as an analysis of baseline LDL-C as a continuous variable comparing ezetimibe + 
simvastatin vs simvastatin alone.
conclusion:  This analysis will determine how LDL-C measured at the time of an ACS event relates to subsequent benefit from the 
addition of ezetimibe to background simvastatin in the IMPROVE IT trial population.
